Last reviewed · How we verify
Hepenofovir Fumarate Tablets Single Dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Hepenofovir Fumarate Tablets Single Dose (Hepenofovir Fumarate Tablets Single Dose) — Xi'an Xintong Pharmaceutical Research Co.,Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hepenofovir Fumarate Tablets Single Dose TARGET | Hepenofovir Fumarate Tablets Single Dose | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hepenofovir Fumarate Tablets Single Dose CI watch — RSS
- Hepenofovir Fumarate Tablets Single Dose CI watch — Atom
- Hepenofovir Fumarate Tablets Single Dose CI watch — JSON
- Hepenofovir Fumarate Tablets Single Dose alone — RSS
Cite this brief
Drug Landscape (2026). Hepenofovir Fumarate Tablets Single Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/hepenofovir-fumarate-tablets-single-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab